Bromoacetamide-PEG3-C1-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Methyltetrazine-PEG4-amine (hydrochloride) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Tetrazine-Ph-SS-amine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Mal-amide-PEG2-oxyamineBoc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Boc-HyNic-PEG2-DBCO is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Boc-HyNic-PEG2-N3 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Boc-HyNic-PEG2-alkyne is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Boc-HyNic-PEG1-mal is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

HyNic-PEG2-DBCO is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

HyNic-PEG2-TCO is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Folate-PEG3-alkyne is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Folate-PEG1-mal is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Folate-PEG3-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Mabuterol-D9 is a deuterium labeled Mabuterol. Mabuterol is an agonist of the β2-adrenergic receptor.

Daclatasvir Impurity C is the impurity of Daclatasvir. Daclatasvir is a potent HCV NS5A protein inhibitor.

Daclatasvir Impurity B is the impurity of Daclatasvir. Daclatasvir is a potent HCV NS5A protein inhibitor.

Monodes(N-carboxymethyl)valine Daclatasvir (Daclatasvir Impurity A) is the main degradation product of Daclatasvir. Daclatasvir is a potent HCV NS5A protein inhibitor.

Oseltamivir acid D3 (GS 4071 D3) is a deuterium labeled Oseltamivir acid. Oseltamivir acid, the active metabolite of Oseltamivir phosphate, is an orally bioavailable, potent and selective inhibitor of influenza virus neuraminidase (IC50=2 nM) with activity against both influenza A and B viruses.

Oseltamivir D3 is a deuterium labeled Oseltamivir. Oseltamivir is an influenza virus neuraminidase inhibitor (NAI). Oseltamivir inhibits influenza A/H3N2, A/H1N2, A/H1N1, and B viruses with mean IC50s of 0.67, 0.9, 1.34 and 13 nM, respectively. Anti-influenza A and B agent.

Oxothiazolidinecarboxylic acid, an antioxidant, is a prodrug of cysteine that is inert until metabolized to cysteine intracellulary, thus stimulating glutathione synthesis.

Rimsulfuron (DPX-E9636) is a sulfonylurea herbicide for postemergence use in maize to control grasses and some broadleaf weeds.

5-Hydroxyferulic acid is a hydroxycinnamic acid and is a metabolite of the phenylpropanoid pathway. 5-Hydroxyferulic acid is a precursor in the biosynthesis of sinapic acid and is also a COMT non-esterifed substrate.

CP-547632 TFA is an orally active, ATP-competitive and potent VEGFR-2 and FGF kinases inhibitor with IC50s of 11 nM and 9 nM, respectively. CP-547632 TFA is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 TFA has antitumor efficacy.

IRAK inhibitor 4 is an interleukin-1 receptor associated kinase 4(IRAK4) inhibitor.

GNF-8625 monopyridin-N-piperazine hydrochloride (TRKi-2), a TRK inhibitor, which is from the patent WO 2020038415 A1.

VEGFR-2-IN-6 (example 64) is a VEGFR2 inhibitor (angiogenesis modulator), which is extracted from patent WO 02/059110.

TPC2-A1-N is a novel, lipophilic, membrane permeable isoform-selective small molecule agonist of two-pore channel 2 (TPC2). TPC2-A1-N plays its role by mimicking the physiological actions of NAADP and PI(3,5)P2?through independent binding sites. TPC2-A1-N has inverse effects on key lysosomal activities and increases the pH in the lysosomal lumen in a TPC2-dependent manner.

Terazosin dimer impurity dihydrochloride, a dimer of Terazosin, is an impurity of Terazosin. Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist.

A3051 is a potent and orally active inhibtor of CXXC5-DVL extracted from patent WO2020079569, has an IC50 of 63.06 nM. A3334 can be used for the research of high fat diet (HFD)-induced and methionine-choline deficient diet (MCD)-induced phenotypes such as obesity, diabetes, and NASH.

Chk1-IN-5 is a potent checkpoint kinase 1 (Chk1) inhibitor. Chk1-IN-5 inhibits Chk1 phosphorylation and inhibits tumor growth in colon cancer xenograft model.